Evidence map›Paper›PMID 26990731›Full record

ArticleArthritis & rheumatology (Hoboken, N.J.)2016

Risk of Herpes Zoster in Autoimmune and Inflammatory Diseases: Implications for Vaccination.

Huifeng Yun, Shuo Yang, Lang Chen, Fenglong Xie, Kevin Winthrop, John W Baddley, Kenneth G Saag, Jasvinder Singh, Jeffrey R Curtis

3 registry-linked trialsOpen access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Arthritis & rheumatology (Hoboken, N.J.), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 112 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
112citing papers in PubMed, 9 pooled it
14.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03016884 phase4unknown statusnot on this mapstarted 2017, after this paper: background citation

Safety and Tolerability of Herpes Zoster Vaccine in Patients With Rheumatoid Arthritis Immunized Prior to Biologics and Tofacitinib Therapy Initiation

TypeinterventionalSponsorHaEmek Medical Center, IsraelRan2017 to 2020Enrolled87ConditionsHerpes ZosterArmsZostavax vaccine
NCT05879419 phase4active not recruitingnot on this mapstarted 2023, after this paper: background citation

Efficacy, Immunogenicity and Safety of Recombinant Vaccine Against Herpes Zoster (RZV or SHINGRIX®) in Patients With Autoimmune Rheumatic Diseases

TypeinterventionalSponsorUniversity of Sao Paulo General HospitalRan2023 to 2032Enrolled2,005ConditionsRheumatoid Arthritis, Spondylitis, Ankylosing, Spondyloarthritis, Systemic Lupus ErythematosusArmsRecombinant Herpes Zoster Vaccine (RZV), MTX Discontinuation, MMF Discontinuation, Placebo, MTX maintain
NCT07280741 phase4recruitingnot on this mapstarted 2025, after this paper: background citation

Efficacy, Immunogenicity, and Safety of the Recombinant Herpes Zoster Vaccine (RZV) in Patients With Autoimmune Rheumatic Diseases Under Immunomodulators

TypeinterventionalSponsorUniversity of Sao Paulo General HospitalRan2025 to 2028Enrolled200ConditionsAutoimmune Rheumatic DiseasesArmsRecombinant Zoster Vaccine (RZV)
3 · Its place in the literature

Who cites it

112 citing papers in PubMed, 9 syntheses or guidelines pooled it, 216 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Guideline
  5. Guideline
  6. Pooled it
  7. Guideline
  8. Guideline
  9. Pooled it
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Observational
  20. Review

52 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Huifeng YunUniversity of Alabama at Birmingham.
Shuo YangUniversity of Alabama at Birmingham.
Lang ChenUniversity of Alabama at Birmingham.
Fenglong XieUniversity of Alabama at Birmingham.
Kevin WinthropOregon Health & Science University, Portland.
John W BaddleyUniversity of Alabama at Birmingham.
Kenneth G SaagUniversity of Alabama at Birmingham.
Jasvinder SinghUniversity of Alabama at Birmingham.
Jeffrey R CurtisUniversity of Alabama at Birmingham.
University of Alabama at Birmingham · USOregon Health & Science University · US

Funding

Longitudinal Comparative Effectiveness & Safety of Biologics in AutoimmunityR01HS018517 · AHRQ · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI CURTIS, JEFFREY R. · 2009 to 2013
$2.2M
UAB K12 in Patient Centered Outcomes ResearchK12HS021694 · AHRQ · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI SAAG, KENNETH G · 2012 to 2013
$900k
AHRQ HHS K12 HS021694AHRQ HHS R01 HS018517
6 · The paper itself

Abstract

objectiveThe herpes zoster (HZ) vaccine is recommended for adults in the US ages ≥60 years who do not have weakened immune systems. It is unclear how the risk of HZ varies according to age and disease conditions in younger patients with autoimmune or inflammatory (AI) diseases. This study was undertaken to evaluate the age-stratified incidence of HZ in patients with AI diseases as compared to older adults for whom the HZ vaccine is currently recommended by the US Centers for Disease Control and Prevention.

methodsUsing linked data obtained from patients who were insured by US commercial and government health care plans during the period 2007-2010, 7 cohorts of patients with AI diseases were assembled: systemic lupus erythematosus (SLE), inflammatory bowel disease (IBD), rheumatoid arthritis (RA), psoriatic arthritis (PsA), psoriasis (PsO), ankylosing spondylitis (AS), and gout. Two comparator cohorts were also assembled as controls: adult patients with diabetes and adult subjects without AI diseases or diabetic conditions. HZ was identified using diagnostic codes. Age-specific incidence rates (IRs) of HZ were calculated and compared to the IRs of HZ in control subjects ages 61-70 years who were without AI diseases or diabetic conditions.

resultsAfter review of the linked data, the following number of enrollment periods were identified: 8,395 for patients with SLE, 7,916 for patients with IBD, 50,646 for patients with RA, 2,629 for patients with PsA, 4,299 for patients with PsO, 1,019 for patients with AS, 58,934 for patients with gout, 214,631 for control patients with diabetes, and 330,727 for control subjects without AI diseases and diabetic conditions. The respective highest and lowest IRs of HZ during the study were 19.9 per 1,000 person-years in the SLE cohort and 6.8 per 1,000 person-years in the gout cohort, as compared to an IR of 5.3 per 1,000 person-years in control subjects without AI diseases or diabetic conditions. The age-specific IRs of HZ in patients with RA and those with SLE ages ≥40 years were 1.5-2 times greater than those observed in older healthy adults (IR 8.5 per 1,000 person-years), for whom the vaccine is currently recommended.

conclusionSLE, IBD, and RA are AI diseases associated with a higher risk of HZ compared to that in older adults for whom vaccination is currently recommended, suggesting that individuals with these conditions who are as young as age 40 years could potentially benefit from the HZ vaccine.

Indexed as

Herpes Zoster VaccineAgedAged, 80 and overAutoimmune DiseasesFemaleHerpes ZosterHumansInflammationMaleMiddle AgedRetrospective StudiesRisk AssessmentHerpes Zoster Vaccine

Identifiers

PMID26990731
PMCPMC5396838
OpenAlexW2297608701

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.